In May 2026, Delhi Police busted a counterfeit medicine racket worth nearly Rs 10 crore — four people arrested for manufacturing and supplying fake life-saving drugs for cancer and liver disease. Fake medicines, packaging equipment, forged labels — all recovered from an operation supplying hospitals across multiple states. Weeks earlier
Breast cancer is now the most commonly diagnosed cancer among Indian women. Within that broad diagnosis, hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer accounts for approximately 60-70% of all cases — and for this large and clinically important group, the treatment landscape has been fundamentally transformed over the past decade by
For most of the past two decades, Indian men diagnosed with advanced prostate cancer had a fairly narrow set of treatment options — hormone therapy, chemotherapy if the cancer progressed, and more recently oral targeted medicines like Enzalutamide (Glenza) and Abiraterone (Abirapro). These are genuinely effective medicines, but they work
In December 2019 the FDA approved a new cancer medicine that most oncologists had never heard of. By 2024 it had become the best-selling antibody-drug conjugate in the world — generating USD 3.75 billion in annual sales. By early 2026 it had received Priority Review for yet another new indication
India’s diabetes and obesity treatment landscape changed dramatically in March 2026. Novo Nordisk’s core Indian patent for semaglutide expired on March 20, 2026 — within hours, a wave of Indian pharmaceutical companies launched their own versions at dramatically lower prices. Branded Ozempic costs ₹8,800–₹11,175 per month in India, while the
When hospitals, clinics, and pharmacies look for a medicine supplier, the most important factor is trust. Counterfeit or substandard medicines are a serious concern in India — and choosing the wrong supplier can put patients at risk. At A.K. Pharma, we understand this responsibility. As a licensed medicine wholesaler in
